Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins
安进终止与协和麒麟在一款免疫学药物上的合作，尽管三期试验告捷

Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year.
安进周五突然退出其免疫学管线中一款领先药物的合作，在今年晚些时候提交给美国食品药品监督管理局之前，将该资产退还给其合作伙伴。